We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.18 | 0.24% | 75.66 | 75.61 | 75.71 | 33,997 | 14:05:12 |
From Apr 2021 to Apr 2024
By Anthony O. Goriainoff
AstraZeneca PLC said Tuesday that Saphnelo has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus, or SLE, who show an insufficient response to standard treatment.
The London-listed biopharmaceutical company said the approval was based on the efficacy and safety data from Saphnelo's clinical development program, and that this is the first regulatory approval by the country's Ministry of Health, Labor and Welfare for a type 1 interferon receptor.
Saphnelo is approved in the U.S. for the treatment of moderate to severe SLE and is under regulatory review for SLE in the EU.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 28, 2021 02:50 ET (06:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
